Go Unlimited with Magzter GOLD

Go Unlimited with Magzter GOLD

Get unlimited access to 10,000+ magazines, newspapers and Premium stories for just

$149.99
 
$74.99/Year

Try GOLD - Free

Kotak PE arm eyes $2 bn fund as private credit demand soars

Mint Mumbai

|

October 02, 2025

Kotak Alternate Assets Managers Ltd is looking to raise a $2 billion fund—Kotak Strategic Solutions Fund (KSSF) III—to provide loans or structured credit to Indian companies.

- Mansi Verma & Sneha Shah

Kotak PE arm eyes $2 bn fund as private credit demand soars

Kotak is also expanding with a ₹4,000-crore yield-and-growth fund and a ₹1,000-crore life sciences fund.

Kotak Mahindra Group's private equity arm plans to lend ₹800-1,000 crore to 12-15 growth-stage companies seeking tailored credit solutions, Easwar Karra, the firm's deputy managing director, said.

The asset manager is in talks with global investors, such as sovereign wealth funds and pension funds, in line with its previous strategies. This time, however, it also plans to raise a portion of the corpus from domestic institutions. Its KSSF I and II were sized at $1 billion and $1.5 billion, respectively.

"We also see strong demand from domestic institutions this time," Karra said. "Credit remains Kotak's mainstay—our domestic underwriting capability has consistently been stronger than most other managers, including banks. Our NPL (nonperforming loans) levels have traditionally been much lower than the industry average," he added.

MORE STORIES FROM Mint Mumbai

Mint Mumbai

Mint Mumbai

Gen Alpha will make new rules for their workplace

Gen Alpha will expect hybrid workplaces, Al tools and 4-day weeks— offices unrecognizable to their parents’

time to read

3 mins

December 01, 2025

Mint Mumbai

EC extends electoral roll revision by a week to II Dec; final list on 14 Feb

The Election Commission on Sunday extended by one week the entire schedule of the ongoing special intensive revision (SIR) of electoral rolls in nine states and three Union territories amid allegations by opposition parties that the “tight timelines” were creating problems for people and ground-level poll officials.

time to read

2 mins

December 01, 2025

Mint Mumbai

THE PROBLEM IS NOT JUST ABOUT DYNASTIC POLITICS

These days Tejashvi Yadav is the target of intense trolling. Before him the Huda family in Haryana and Thackerays in Maharashtra got the same treatment. So, is the battle of victory and defeat in electoral politics a tussle between dynasts vs the rest? Absolutely not.

time to read

3 mins

December 01, 2025

Mint Mumbai

Mint Mumbai

Green hydrogen: Fast fashion could help bump up demand

A boom in its use for clean synthetic inputs might make a difference

time to read

3 mins

December 01, 2025

Mint Mumbai

Let's be a bit more selective in using the word 'reforms'

Everybody should take a beat and think before uttering the word ‘reforms’ the next time. Glib usage, frequently in the wrong context, threatens to rob the word of its import.

time to read

3 mins

December 01, 2025

Mint Mumbai

As mid-cap alpha shrinks, should you consider passive strategies?

Advisers urge a balanced mix—add passives slowly and back strong, active managers, as mid-caps are still pricey

time to read

4 mins

December 01, 2025

Mint Mumbai

Mint Mumbai

With $2.2 bn fund, ChrysCap has appetite for riskier bets

MD Saurabh Chatterjee details shift in global LP base, renewed focus on manufacturing

time to read

3 mins

December 01, 2025

Mint Mumbai

GDP growth of 8% plus: How to sustain this pace

Last quarter's economic expansion has cheered India but the challenge is to sustain a brisk rate for years to come. For private investment to chip in, revive infrastructure partnerships

time to read

2 mins

December 01, 2025

Mint Mumbai

INSIDE INDIA'S ATTEMPT TO TAME DEEPFAKES

Detection tools today are not universal or consistent across languages

time to read

5 mins

December 01, 2025

Mint Mumbai

Mint Mumbai

APIs to innovation: Bulk drug makers ramp up CDMO bets

Once focused on low-margin active pharmaceutical ingredients (APIs), India’s bulk drug manufacturers are raising their ambitions, with several now investing heavily in research and development to win contract development and manufacturing work from global drugmakers.

time to read

2 mins

December 01, 2025

Listen

Translate

Share

-
+

Change font size